Clinical Trial Update: Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

View source ↗

Summary

Ipsen-sponsored clinical trial evaluating cabozantinib in participants with neuroendocrine tumors who have received prior treatment is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Ipsen | Conditions: Neuroendocrine Tumors | Status: RECRUITING